Fighting Infection in a Globalized World
Probably the hardest human battle, one that has lasted hundreds of thousands of years, has been the one against infection. Being able to celebrate a 30 th birthday was once considered a miracle but only if one survived the perilous years of childhood. Indeed, the CDC reports that in 1900, nearly 30% of deaths worldwide occurred in children 5 and under. It is remarkable how far we've come in our ability to fight off pathogens. Better nutrition, medication, sanitation, and overall quality of life has meant that humans are now living longer than ever before in history. Smallpox, one of the deadliest diseases of the 20 th century was successfully eradicated in 1977, and we are close with polio. Vaccinations against once-deadly diseases such as rubella, bacterial meningitis, measles, and tuberculosis have drastically slashed early deaths.
Yet, according to the World Health Organization, infectious diseases continue to kill nearly 15 million people every year. Newer influenza strains, SARS, and Nipah outbreaks among others created major public health scares in the last decade. The fact is that the highly connected and overpopulated world of today has facilitated the swift spread of deadly pathogens, often enforcing quick adaptation to new hosts and conditions. This means that even with the advances in medication and vaccination, we need better surveillance and attention to outbreaks anywhere, however faraway they may seem. Improved surveillance will lead to better preparation for disease containment and treatment. This point has been exemplified over the last 3 years across four continents and two very different viruses-Ebola and Zika.
Viruses that cause hemorrhagic fevers such as Ebola, Lassa, and yellow fever recur every few years, often unfortunately and inevitably with a certain death toll; however, the Ebola outbreak in West Africa from 2014 onward has been the biggest of its kind, killing nearly 12,000 people across several countries. With one of the highest mortality rates for a virus, the spread of Ebola and the lack of available drugs, vaccines, or clear treatment options soon became a major global concern. People traveling to and from West Africa, including medical personnel, needed to be monitored and even quarantined out of fear that the outbreak would spread to the rest of the world.
The biology and structure of Ebolavirus is fairly wellstudied, and a number of studies have aimed to use DNA and adenoviral vector-based vaccines in animal models (Sullivan et al., 2003) . More recently, the focus has been toward single monoclonal antibodies against specific viral proteins. During the latter part of the recent outbreak, scientists saw some promise in the use of ZMapp, a combination of three monoclonal antibodies targeting the Ebolavirus surface glycoprotein (GP) (Qiu et al., 2014) . A recent study in Science takes a leap forward toward effective viral targeting through the design of bispecific antibodies-recombinant proteins that consist of two antibodies that bind different antigens thereby strengthening the antigen-antibody interation for effective targeting. In this study, the authors designed bispecific antibodies targeting the Ebolavirus GP as well as the host receptor that it binds (NPC1) that showed a remarkable ability to neutralize various strains of Ebola in vivo in animal models (Wec et al., 2016) . This strategy may be used to target additional members of this and other families of viruses if either the host targets are shared or viral proteins bear high homology, such as the VP40 matrix protein, that has conserved sequences between Ebolavirus and the equally deadly Marburg virus. An extra advantage of this approach by the authors also seems to be that it could be effective to target viral proteins that are routed through endosomal pathways or those with intracellular receptors (Wec et al., 2016) .
If 2014-2015 was about Ebola, 2016 has been about Zika virus, the milder and relatively unknown cousin of Dengue. In sharp contrast to Ebola, adults with Zika virus experience only a mild illness and no deaths directly linked to the virus had even been heard of. Yet there was a disturbing observation. There appeared to be a marked increase in the number of infants born with severe neurological abnormalities to women who were infected with Zika during their pregnancy (Solomon et al., 2016) . Was there more to this otherwise innocuous virus? Growing evidence suggested that the virus could persist in semen of men infected with Zika, and therefore had the potential to be sexually transmitted (D'Ortenzio et al., 2016) . The need of the hour has thus been a vaccine that can be administered to adults to establish immunity, and in women, especially, well-before any pregnancy. A number of labs have made inroads toward studying antibody-mediated protection against Zika. The similarity to Dengue meant that there was some level of cross-reactivity between the two viruses, though recent work has focused on Zika-specific potent antibodies (Barba-Spaeth et al., 2016 and Zhao et al., 2016) . Vaccine efforts in animal models have been promising: using purified inactivated viruses showed protection in mouse and primate models specifically to the Zika strains associated with the current outbreak Larocca et al., 2016) . More recently, a paper in Science reports a DNA-based vaccine that works through expressing the precursor membrane (prM) and envelope (E) proteins of Zika virus, also conferring protection in mice and non-human primates . However none of these studies have yet tested the protective efficacy in pregnant animals and whether the vaccination can indeed
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There will be more pathogens, emerging and re-emerging, but the lessons learned from these outbreaks as well as strategies involved toward developing successful vaccinations will undoubtedly be helpful if the need arises.
